54.37
price up icon0.80%   0.43
pre-market  Pre-market:  54.76   0.39   +0.72%
loading
Biomarin Pharmaceutical Inc stock is traded at $54.37, with a volume of 2.71M. It is up +0.80% in the last 24 hours and down -5.51% over the past month. BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$53.94
Open:
$53.85
24h Volume:
2.71M
Relative Volume:
1.28
Market Cap:
$10.44B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
20.21
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-0.24%
1M Performance:
-5.51%
6M Performance:
-24.01%
1Y Performance:
-22.93%
1-Day Range:
Value
$53.62
$55.18
1-Week Range:
Value
$52.94
$56.07
52-Week Range:
Value
$52.93
$73.51

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Name
Name
Biomarin Pharmaceutical Inc
Name
Phone
(415) 506-6700
Name
Address
105 DIGITAL DRIVE, NOVATO, CA
Name
Employee
3,040
Name
Twitter
Name
Next Earnings Date
2024-10-29
Name
Latest SEC Filings
Name
BMRN's Discussions on Twitter

Compare BMRN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
54.37 10.36B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
387.15 100.34B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.50 60.95B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
451.73 60.46B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
734.35 46.04B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
332.20 36.02B 3.81B -644.79M -669.77M -6.24

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-08-25 Initiated H.C. Wainwright Neutral
Sep-03-25 Initiated Raymond James Outperform
Jul-03-25 Resumed Morgan Stanley Overweight
Feb-24-25 Upgrade Oppenheimer Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Oct-30-24 Downgrade William Blair Outperform → Mkt Perform
Oct-10-24 Resumed Raymond James Outperform
Aug-20-24 Upgrade Bernstein Mkt Perform → Outperform
May-17-24 Downgrade Robert W. Baird Outperform → Neutral
May-14-24 Initiated Evercore ISI Outperform
Nov-15-23 Initiated Wells Fargo Overweight
Oct-23-23 Upgrade Bernstein Underperform → Mkt Perform
Sep-28-23 Initiated Raymond James Mkt Perform
Sep-18-23 Initiated UBS Buy
Jul-27-23 Initiated Scotiabank Sector Perform
Jul-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Jun-14-23 Resumed Credit Suisse Outperform
Mar-21-23 Initiated Bernstein Underperform
Feb-22-23 Downgrade Oppenheimer Outperform → Perform
Feb-21-23 Initiated Citigroup Neutral
Jan-30-23 Initiated BMO Capital Markets Market Perform
Jan-18-23 Initiated Canaccord Genuity Hold
Oct-31-22 Upgrade Oppenheimer Perform → Outperform
Jul-13-22 Initiated Cantor Fitzgerald Overweight
Jun-13-22 Resumed Wedbush Neutral
Apr-25-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-22-21 Upgrade William Blair Mkt Perform → Outperform
Oct-07-21 Resumed Jefferies Buy
Sep-09-21 Upgrade Stifel Hold → Buy
Jun-04-21 Resumed Robert W. Baird Outperform
Apr-26-21 Resumed Credit Suisse Outperform
Mar-04-21 Resumed Guggenheim Buy
Mar-01-21 Upgrade Evercore ISI In-line → Outperform
Aug-20-20 Downgrade Citigroup Buy → Neutral
Aug-20-20 Downgrade William Blair Outperform → Mkt Perform
Aug-19-20 Downgrade Evercore ISI Outperform → In-line
Aug-19-20 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20 Downgrade Stifel Buy → Hold
Jul-08-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-06-20 Reiterated Citigroup Buy
Jan-28-20 Initiated BMO Capital Markets Market Perform
Jan-27-20 Initiated BMO Capital Markets Market Perform
Jan-24-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-27-19 Upgrade Barclays Equal Weight → Overweight
Nov-12-19 Initiated SunTrust Buy
Oct-17-19 Resumed BofA/Merrill Buy
May-23-19 Resumed Citigroup Buy
Apr-09-19 Resumed Raymond James Outperform
Jan-02-19 Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18 Initiated Wolfe Research Outperform
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-07-18 Reiterated Stifel Buy
Aug-03-18 Reiterated Stifel Buy
View All

Biomarin Pharmaceutical Inc Stock (BMRN) Latest News

pulisher
Sep 17, 2025

BMO Capital Reiterates a Buy on BioMarin Pharmaceutical (BMRN) - MSN

Sep 17, 2025
pulisher
Sep 17, 2025

Acadian Asset Management LLC Has $1.70 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 17, 2025
pulisher
Sep 17, 2025

Intech Investment Management LLC Has $2.27 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 17, 2025
pulisher
Sep 17, 2025

Goldman Sachs Group Inc. Acquires 1,083,512 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 17, 2025
pulisher
Sep 17, 2025

Alliancebernstein L.P. Buys 61,594 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 17, 2025
pulisher
Sep 16, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Cuts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 16, 2025
pulisher
Sep 16, 2025

BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory - Yahoo Finance

Sep 16, 2025
pulisher
Sep 16, 2025

New Study Results Highlight BioMarin’s VOXZOGO Efficacy in Children - Yahoo Finance

Sep 16, 2025
pulisher
Sep 16, 2025

Bayforest Capital Ltd Purchases New Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 16, 2025
pulisher
Sep 16, 2025

Wesbanco Bank Inc. Increases Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 16, 2025
pulisher
Sep 16, 2025

Revenue Check: Is BioMarin Pharmaceutical Inc part of any major indexJuly 2025 Macro Moves & Consistent Return Investment Signals - خودرو بانک

Sep 16, 2025
pulisher
Sep 15, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com

Sep 15, 2025
pulisher
Sep 15, 2025

Portfolio Update: Can BioMarin Pharmaceutical Inc scale operations efficientlyChart Signals & Reliable Breakout Forecasts - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

Guidance Update: How does BioMarin Pharmaceutical Inc score in quality rankingsQuarterly Portfolio Review & Weekly High Return Forecasts - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

Published on: 2025-09-15 20:38:06 - خودرو بانک

Sep 15, 2025
pulisher
Sep 15, 2025

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 9,837 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 15, 2025
pulisher
Sep 15, 2025

BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat

Sep 15, 2025
pulisher
Sep 14, 2025

Clearline Capital LP Decreases Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 14, 2025
pulisher
Sep 13, 2025

Biomarin’s Market Mismatch: Strong Fundamentals Clash With Share Price Weakness - AD HOC NEWS

Sep 13, 2025
pulisher
Sep 13, 2025

HC Wainwright Begins Coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) - MarketBeat

Sep 13, 2025
pulisher
Sep 13, 2025

BioMarin (BMRN): Valuation in Focus After New VOXZOGO and PALYNZIQ Study Results Boost Confidence - Sahm

Sep 13, 2025
pulisher
Sep 12, 2025

Teza Capital Management LLC Makes New $723,000 Investment in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 12, 2025
pulisher
Sep 12, 2025

Federation des caisses Desjardins du Quebec Has $1.52 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 12, 2025
pulisher
Sep 12, 2025

Parkman Healthcare Partners LLC Buys Shares of 277,252 BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 12, 2025
pulisher
Sep 12, 2025

NFJ Investment Group LLC Buys New Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 12, 2025
pulisher
Sep 11, 2025

Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Black Diamond Therapeutics (BDTX) - The Globe and Mail

Sep 11, 2025
pulisher
Sep 11, 2025

28,736 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Cinctive Capital Management LP - MarketBeat

Sep 11, 2025
pulisher
Sep 10, 2025

Could Recent Clinical Progress Reshape BioMarin’s (BMRN) Long-Term Competitive Edge in Rare Diseases? - Sahm

Sep 10, 2025
pulisher
Sep 09, 2025

Narrow-Moat BioMarin Supported by Voxzogo and Rare-Disease Pipeline - Morningstar

Sep 09, 2025
pulisher
Sep 09, 2025

Biomarin at Morgan Stanley Conference: Strategic Growth and Innovation By Investing.com - Investing.com South Africa

Sep 09, 2025
pulisher
Sep 09, 2025

Biomarin at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com

Sep 09, 2025
pulisher
Sep 09, 2025

Graham Capital Management L.P. Takes Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 09, 2025
pulisher
Sep 09, 2025

Vident Advisory LLC Makes New Investment in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 09, 2025
pulisher
Sep 09, 2025

AQR Capital Management LLC Purchases 1,642,206 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 09, 2025
pulisher
Sep 08, 2025

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting - Lelezard

Sep 08, 2025
pulisher
Sep 08, 2025

Are Options Traders Betting on a Big Move in BioMarin Pharmaceutical Stock? - sharewise.com

Sep 08, 2025
pulisher
Sep 08, 2025

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment - Benzinga

Sep 08, 2025
pulisher
Sep 08, 2025

Why BioMarin Pharmaceutical (BMRN) Stock Is Down Today - Yahoo Finance

Sep 08, 2025
pulisher
Sep 08, 2025

BioMarin Says Data Showing Voxzogo's Benefits in Children With Achondroplasia - MarketScreener

Sep 08, 2025
pulisher
Sep 08, 2025

This Duolingo Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga

Sep 08, 2025
pulisher
Sep 07, 2025

BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN

Sep 07, 2025
pulisher
Sep 07, 2025

Palo Alto Investors LP Lowers Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 07, 2025
pulisher
Sep 06, 2025

BioMarin’s PKU drug shows nearly 50% blood Phe reduction in teens - Investing.com Nigeria

Sep 06, 2025
pulisher
Sep 06, 2025

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism - Yahoo Finance

Sep 06, 2025
pulisher
Sep 06, 2025

Why is BioMarin Pharmaceutical Inc. stock going upInflation Watch & Fast Moving Market Watchlists - خودرو بانک

Sep 06, 2025
pulisher
Sep 06, 2025

Canada Pension Plan Investment Board Increases Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat

Sep 06, 2025
pulisher
Sep 06, 2025

What is BioMarin Pharmaceutical Inc.’s book value per shareJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - خودرو بانک

Sep 06, 2025

Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$35.64
price up icon 0.62%
$84.80
price up icon 1.07%
$28.08
price down icon 0.57%
$98.15
price down icon 1.12%
$144.78
price up icon 0.02%
biotechnology ONC
$332.20
price up icon 1.53%
Cap:     |  Volume (24h):